Epygenix Candidates in Clinical Trials
Our pipeline of candidates includes multiple innovative drugs at varying stages of development. Our lead investigational drug, EPX-100, is currently in a pivotal Phase 2 clinical trial for Dravet Syndrome (DS) and Phase 2 planning for Lennox-Gastaut Syndrome (LGS) is underway, with a projected launch date in 2023.
Learn more about a Phase 2 Study for Dravet syndrome
Learn more about our clinical program on clinicaltrials.gov